

# Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins

Puay Hoon Tan,<sup>1</sup> Aye Aye Thike,<sup>1</sup> Wai Jin Tan,<sup>1</sup> Minn Minn Myint Thu,<sup>1</sup> Inny Busmanis,<sup>1</sup> HuiHua Li,<sup>2</sup> Wen Yee Chay,<sup>3</sup> Min-Han Tan,<sup>4</sup> The Phyllodes Tumour Network Singapore\*

<sup>1</sup>Department of Pathology, Singapore General Hospital, Singapore

<sup>2</sup>Department of Clinical Research, Singapore General Hospital, Singapore

<sup>3</sup>Department of Medical Oncology, National Cancer Centre Singapore, Singapore

<sup>4</sup>Institute of Bioengineering and Nanotechnology, Singapore

## Correspondence to

Dr Puay Hoon Tan, Department of Pathology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore; [tan.puay.hoon@sgh.com.sg](mailto:tan.puay.hoon@sgh.com.sg)

\*Phyllodes Tumour Network Singapore:  
Benita Tan, FRCS  
Chow Yin Wong, FRCS  
Department of General Surgery, Singapore General Hospital  
Kong Wee Ong, FRCS  
Wei Sean Yong, FRCS  
Gay Hui Ho, FRCS  
Department of Surgical Oncology, National Cancer Centre Singapore  
Wei Seong Ooi, MRCP  
Department of Medical Oncology, National Cancer Centre Singapore  
Bin Tean Teh, PhD  
National Cancer Centre—Van Andel Research Institute Translational Research Laboratory, Singapore.

Accepted 24 August 2011  
Published Online First  
2 November 2011

## ABSTRACT

**Aim** To define a predictive model for clinical behaviour of breast phyllodes tumours (PT) using histological parameters and surgical margin status.

**Methods** Cases of breast PT diagnosed in the Department of Pathology Singapore General Hospital between January 1992 and December 2010 were stratified into benign, borderline and malignant grades based on a combination of histological parameters (stromal atypia, hypercellularity, mitoses, overgrowth and nature of tumour borders). Surgical margin status was assessed. Clinical follow-up and biostatistical modelling were accomplished.

**Results** Of 605 PT, 440 (72.7%) were benign, 111 (18.4%) borderline and 54 (8.9%) malignant. Recurrences, which were predominantly local, were documented in 80 (13.2%) women. Deaths from PT occurred in 12 (2%) women. Multivariate analysis revealed stromal atypia, overgrowth and surgical margins to be independently predictive of clinical behaviour, with mitoses achieving near significance. Stromal hypercellularity and tumour borders were not independently useful. A nomogram developed based on atypia, mitoses, overgrowth and surgical margins (AMOS criteria) could predict recurrence-free survival at 1, 3, 5 and 10 years. This nomogram was superior to a total histological score derived from adding values assigned to each of five histological parameters.

**Conclusion** A predictive nomogram based on three histological criteria and surgical margin status can be used to calculate recurrence-free survival of an individual woman diagnosed with PT. This can be applied for patient counselling and clinical management.

## INTRODUCTION

Phyllodes tumours (PT) are uncommon, biphasic, fibroepithelial lesions of the breast, characterised by leafy stromal fronds capped by benign bilayered epithelium.<sup>1 2</sup> While they resemble the innocuous intracanalicular fibroadenoma, they need to be distinguished and separately recognised because of their recurrent and possible metastatic potential.<sup>3–6</sup> PT account for <1% of all primary breast neoplasms, although in Asian countries, they appear to be more frequently encountered,<sup>1</sup> with a reported younger age of occurrence.<sup>7</sup> Classification into benign, borderline and malignant categories is based on a constellation of histological parameters that primarily focuses on stromal features of atypia, mitoses, cellularity, overgrowth

and nature of tumour margins.<sup>1 2 8 9</sup> The attention on stromal features is premised on the view that the stroma of PT represents the neoplastic component that progresses and which is responsible for clinical behaviour.<sup>10–16</sup> It is increasingly acknowledged, however, that there are epithelial–stromal interactions that play an important role in the pathogenesis of these tumours.<sup>11 12 17 18</sup>

Apart from many reports of biological and genetic markers that can assist in categorising or grading PT for prognostic purposes,<sup>8 9 19–30</sup> classification of this group of tumours remains problematic in terms of standardised universal application. How the assessment of each histological parameter combines together to assign a specific grade, and whether there are histological features that are individually more important in predicting recurrent behaviour, have not been resolved.<sup>1 31–36</sup> As such, the management of these tumours remains challenging.


In this study, we evaluate the clinicopathological features, review the follow-up of a large series of breast PT from a single institution and propose a model that can assist in individual prediction of clinical behaviour.

## METHODS

### Patients and tumours


Cases of breast PT diagnosed between January 1992 and December 2010 were derived from the files of the Department of Pathology, Singapore General Hospital. Patient details and tumour laterality were determined from accession forms, while tumour size was obtained from surgical pathology reports. In general, at least one block per centimetre of tumour was sampled for microscopic examination. Histological classification into benign, borderline and malignant categories relied on the degree of stromal hypercellularity, cytologic atypia, mitotic activity, stromal overgrowth and nature of the borders (circumscribed vs permeative). A circumscribed border was characterised by a pushing margin that protruded or bulged against the surrounding breast tissue (figure 1); conversely, a permeative border was one in which extensions of tumour crept into adjacent tissue without a well-defined interface between tumour and non-lesional tissue (figure 2). Stromal hypercellularity and cytologic atypia were categorised as mild, moderate and marked.<sup>4</sup> Stromal mitotic activity was quantified per 10 high-power fields (hpf) of the

## Original article




**Figure 1** Benign phyllodes tumour shows a pushing margin with a circumscribed rounded border at the interface with adjacent breast tissue.

microscope objective ( $\times 40$  objective and  $\times 10$  eyepiece,  $0.196 \text{ mm}^2$ ), in the most mitotically active areas of the stroma (figure 3). Stromal overgrowth, defined as a low-power field ( $\times 4$  microscope objective and  $\times 10$  eyepiece,  $22.902 \text{ mm}^2$ ) that comprised only stroma without epithelial elements, was deemed absent or present (figure 4). A benign PT was diagnosed when the lesion showed pushing margins, mild or moderate stromal hypercellularity, mild or moderate stromal cytologic atypia, occasional mitoses that numbered up to 4 per 10 hpf and no stromal overgrowth. A malignant tumour was defined by marked stromal hypercellularity and cytologic atypia, presence of stromal overgrowth, brisk mitotic activity (10 or more per 10 hpf) and permeative margins; the finding of a malignant heterologous element placed the tumour into a malignant category. Borderline PT showed some but not all the characteristics observed in malignant lesions. Whether there was pseudoangiomatous stromal hyperplasia within the tumour was documented. The presence of heterologous stromal elements was documented. Multifocality was defined by presence of discrete PT separated by non-lesional breast tissue.



**Figure 2** A phyllodes tumour, classified as borderline, reveals stromal extensions into the surrounding adipose tissue.




**Figure 3** A malignant phyllodes tumour with brisk mitotic activity amid stromal cells with generally moderate nuclear atypia.

The surgical procedure was defined from accession forms. Surgical margins, based on available histological material, were evaluated as complete, when sections sampled showed a surrounding rim of non-lesional breast tissue; focally involved, when tumour extended in only one focus to the inked or cauterised surgical margin or diffusely involved, when the surgical margin was breached by tumour in more than one focus. Focal and diffuse surgical margin involvement was combined for statistical analysis. In women who underwent a further follow-up surgery, surgical margin status was assessed in the latter pathologic specimen. Adjuvant radiation or chemotherapy was not routine treatment.

Patient follow-up was derived from medical records and any deaths determined from the National Registries of Births and Deaths. Recurrences were either local (at the original site of diagnosis of PT) or distant (metastases).

#### Total histological score

Scores were assigned to the five histological parameters of stromal hypercellularity, stromal atypia, mitotic rate, stromal overgrowth and nature of borders. Mild, moderate and marked



**Figure 4** A low-power microscope field of stroma only, devoid of epithelial elements, indicating stromal overgrowth.



stromal hypercellularity and stromal atypia were each scored from 1 to 3, respectively. Mitotic rates of 0–4, 5–9 and  $\geq 10$  per 10 hpf were given scores of 1 to 3, respectively. Absence or presence of stromal overgrowth and pushing versus permeative margins were regarded as 1 and 2 in their respective categories. The total histological score was defined as a sum of the score for each of the five histological parameters and ranged from a minimum of five to a maximum of 13, with a higher histological score expected to portend a worse prognosis, based on an assumption that the various histological parameters had an additive effect.

### Statistical analysis

Kaplan–Meier survival curves were used to estimate recurrence-free survival (RFS), which was defined as the time from date of surgery to date of first relapse or death from PT or to the last follow-up date for censored cases. Univariable and multivariable Cox regression analyses were performed to evaluate the effects of potential predictors on RFS.

We used a previously described general approach to model evaluation.<sup>37</sup> Briefly, reduced model selection was carried out using a backward stepdown by applying the stopping rule of Akaike's information criterion (AIC). Proportional hazards assumptions were verified systematically for all proposed models. Multivariate Cox regression coefficients were used to generate the nomogram. The ability of the nomogram to predict RFS of individual patients was evaluated with bootstrapping of 200 bootstrap set of resamples. Calibration plots were generated to explore the performance characteristics of the nomogram at 1, 3, 5 and 10 years after surgery.

We compared the performance of this model with total histological score using c-indices and likelihood ratio (LR) analysis. We used LR  $\chi^2$  of nested models to perform pairwise comparisons between our nomogram and the total score. An adequacy index using LR methods was used to quantify the percentage of the predictive information explained by a subset of the individual predictors (nomogram or total histological score) compared with the information contained in the full set of predictors (nomogram and total histological score) by means of log-likelihood. Harrell's c-index was calculated to evaluate the concordance between predicted and observed responses of individual subjects separately. All analyses were done using R V.2.13.0 (<http://www.R-project.org>) and STATA V.11.

### RESULTS

There were a total of 605 cases of PT during the study period, all occurring in women, with a median age of 43 years. There were 440 (72.7%) benign, 111 (18.4%) borderline and 54 (8.9%) malignant tumours. The right and left breasts were affected in 310 (51.2%) and 293 (48.5%) of cases, respectively, with bilateral disease observed in two (0.3%) women. The microscopic features of the bilateral tumours were almost identical in each case, with one woman having her right and left benign tumours differing only in size (4, 6 cm), mitotic rate (one and four mitoses per 10 hpf) and surgical margin status (complete excision versus focal involvement), while the other woman's bilateral benign tumours also differed only in size (right 2.5 cm, left 2.2 cm) and epithelial hyperplasia (mild vs none).<sup>1</sup> For statistical analysis, the right tumours were used. Clinicopathological characteristics stratified according to PT grade are presented in table 1. Older patient age and larger tumour size were observed more frequently in borderline and malignant PT ( $p < 0.001$ ). Heterologous elements were found in 12 malignant PT, comprising five with liposarcoma, two osteosarcoma, two

**Table 1** Clinicopathological features of 605 cases of phyllodes tumour stratified according to histological grade

Clinicopathological features	Benign	Borderline	Malignant	p Value
Age (years) (mean 42, median 43, range 15–79)				<0.001
<mean age	227 (37.5%)	36 (5.9%)	16 (2.6%)	
$\geq$ mean age	213 (35.2%)	75 (12.5%)	38 (6.3%)	
Ethnicity				0.724
Chinese	307 (50.7%)	81 (13.4%)	37 (6.1%)	
Malay	66 (11.2%)	19 (3.1%)	10 (1.6%)	
Indian	31 (5.1%)	3 (0.5%)	0 (0%)	
Others	36 (5.9%)	8 (1.3%)	7 (1.1%)	
Size (mm) (mean 52, median 40, range 3–250)				<0.001
<mean size	343 (56.7%)	54 (8.9%)	16 (2.6%)	
$\geq$ mean size	97 (16.1%)	57 (9.4%)	38 (6.3%)	
Microscopic borders				<0.001
Circumscribed	283 (46.8%)	49 (8.1%)	20 (3.3%)	
Permeative	157 (26.0%)	62 (10.2%)	34 (5.6%)	
Stromal hypercellularity				<0.001
Mild	302 (49.9%)	21 (3.5%)	3 (0.5%)	
Moderate	131 (21.7%)	75 (12.4%)	25 (4.1%)	
Marked	7 (1.1%)	15 (2.5%)	26 (4.3%)	
Stromal atypia				<0.001
Mild	412 (68.1%)	54 (8.9%)	0 (0%)	
Moderate	28 (4.8%)	54 (8.9%)	30 (4.9%)	
Marked	0 (0%)	3 (0.5%)	24 (3.9%)	
Stromal overgrowth				<0.001
Absent	440 (72.8%)	86 (14.2%)	14 (2.3%)	
Present	0 (0%)	25 (4.1%)	40 (6.6%)	
Mitotic activity/10 hpf				<0.001
0–4	402 (66.4%)	31 (5.1%)	5 (0.8%)	
5–9	34 (5.6%)	51 (8.4%)	15 (2.5%)	
$\geq 10$	4 (0.7%)	29 (4.9%)	34 (5.6%)	
Surgical margins				0.511
Complete (Not involved)	257 (42.5%)	58 (9.6%)	34 (5.6%)	
Focal involvement	168 (27.7%)	44 (7.3%)	16 (2.6%)	
Diffuse involvement	15 (2.5%)	9 (1.5%)	4 (0.7%)	

hpf, high-power fields.

chondrosarcoma, one rhabdomyosarcoma and the remaining with a combination of these components. Multifocality with two discrete PT was observed in six (1.6%) women. This was distinguished from a multilobulated appearance which may be visualised at the outer tumour contours.

Recurrences were noted in 80 (13.2%) women (table 2). Mean and median times to recurrence were 29.8 and 24.6 months, respectively. Additional details of recurrent tumours are provided in tables 3–7. Deaths were documented in 19 women, 12 of which were due to PT and the remaining seven from non-PT-related causes.

For statistical analysis, 552 patients were included after discounting 19 non-local residents without follow-up information as their follow-up status could not be accurately determined and those in whom follow-up was <3 months. The final median follow-up for this group of women was 56.9 months with

**Table 2** Relationship of grade of phyllodes tumour with recurrence ( $p < 0.001$ )

Grade of phyllodes tumour	Absent	Present	Total
Benign	392 (89.1%)	48 (10.9%)	440 (100%)
Borderline	95 (85.6%)	16 (14.4%)	111 (100%)
Malignant	38 (70.4%)	16 (29.6%)	54 (100%)
Total	525 (86.8%)	80 (13.2%)	605 (100%)

## Original article

**Table 3** Pattern of recurrence, both local and distant (metastases) of PT

Pattern	Number (%)
Local recurrence	68 (85%)
Metastases	7 (8.7%)
Local recurrence & metastases	5 (6.3%)
Total	80 (100%)

PT, phyllodes tumours.

a range of 3.3–229.2 months. Univariate analysis showed that mitotic rate, grade, surgical margin, atypia, hypercellularity, overgrowth and borders affected RFS significantly (table 8). While PT grade was also significantly associated with RFS, we did not incorporate it in the model as grade is derived from multiple histological parameters for which deconstruction into individual factors avoids combinational variability. Following reduced model selection by the AIC stopping rule, multivariate analysis showed that atypia, overgrowth and surgical margin significantly affected RFS significantly, but not hypercellularity or tumour borders (table 9). Mitotic rate was close to statistical significance ( $p=0.058$ ). We thus excluded stromal hypercellularity and tumour borders from the final model, with the additional considerations that log-likelihood ratio test showed that adding hypercellularity or tumour borders into the model would not significantly improve that incorporating stromal atypia, mitotic rate, stromal overgrowth and surgical margin only ( $p=0.0645$ ,  $p=0.3289$ , respectively). The nomogram derived based on the multivariate Cox regression coefficients is shown (figure 5). Figure 6A–D demonstrates the bootstrap estimates of calibration accuracy for 1-, 3-, 5- and 10-year RFS estimates from the final Cox model. The comparison of our nomogram and total histological score showed that the nomogram with a higher C-index predicted RFS better than total histological score (tables 10 and 11). LR testing also showed that our nomogram provided superior estimates relative to total histological score, as the inclusion of nomogram to the model with total histological score only resulted in a highly statistically improvement ( $p<0.0001$ ), compared with the inclusion of total histological score to the model with nomogram only ( $p=0.6381$ ) as pictorially depicted in figure 7. Using the log LR test, we confirmed that the addition of surgical margin status significantly improved our model ( $p<0.0001$ ). For cases with negative surgical margins, the nature of tumour borders (circumscribed or permeative) was not predictive of RFS ( $p=0.1110$ ).

## DISCUSSION

Grading of PT has been widely used to categorise these tumours into prognostic groups. Benign PT are known to potentially recur locally, while borderline and malignant ones have both recurrent and metastatic ability, with deaths from PT often preceded by distant metastases.<sup>1 2</sup> While grade has predictive utility across cohorts, with quoted recurrence rates of 17%, 25% and 27% in benign, borderline and malignant PT,<sup>2</sup> information on likely

**Table 4** Frequency of recurrence of PT

Frequency of recurrences	Number (%)
1	52 (65%)
2	23 (28.8%)
3	4 (5%)
6	1 (1.2%)
Total	80 (100%)

PT, phyllodes tumours.

**Table 5** Recurrent pattern stratified according to the grade of PT

Grade	Local recurrence	Metastases	Local recurrence and metastases
Benign	48	0	0
Borderline	16	0	0
Malignant	4	7	5
Total	68	7	5

PT, phyllodes tumours.

recurrent behaviour in an individual patient is uncertain. In our current study, we found recurrences in 80 (13.2%) cases, the vast majority being local in nature (73 out of 80 cases, 91.2%), with metastatic disease occurring consequent to local recurrence in 5 (6.3%) cases and identified after a diagnosis of malignant PT in 7 (8.7%) cases. Overall, recurrences occurred in 10.9% of benign, 14.4% of borderline and 29.6% of malignant PT, lending credence to the ability of grade to predict clinical behaviour.

The issue with grade, however, is with inherent challenges to reproducibility. It is generally agreed that stromal characteristics of atypia, mitoses, cellularity, overgrowth and nature of tumour margins are key parameters in determining grade. Assessment of atypia and cellularity may be hampered by interobserver variability. Evaluation of mitoses, too, may have concerns about the number of fields to be analysed and whether it should be a maximal or average mitotic count. Stromal overgrowth, while appearing the least contentious, may possibly vary due to differences in the size of the low-power microscopic field. Many of these perceived problems are related to the lack of clear definition. While these can be rectified through enunciation of more clearly defined histological criteria, there is the additional difficulty of how various parameters are integrated into a final microscopic grade. At the extreme ends of the spectrum, the diagnosis of grade is mostly straightforward. For example, a tumour with modest stromal atypia, low cellularity and mitoses, with pushing margins and without stromal overgrowth, is unequivocally benign. In contrast, for a PT with marked stromal atypia, high cellularity and mitotic activity, with permeative margins and stromal overgrowth, a malignant diagnosis can be readily rendered. In the intermediate range, however, it is difficult to accurately assign a grade, and it may become a judgement call based on the parameter(s) believed to have stronger biological weightage. Regardless of its value, grade is unable to predict clinical behaviour in an individual patient diagnosed with PT.

Surgical margins have been regarded as a critical element in impacting the likelihood of PT recurrence.<sup>1 32 36 38–42</sup> This is affirmed in our current study which shows independent significance of surgical margins on RFS on multivariate analysis.

It is with the knowledge of existing deficiencies in PT classification and behaviour prediction that we embarked on this effort to simplify the evaluation of histological parameters in determining grade, omitting those that may already be

**Table 6** Sites of metastases of PT

Site	Number (%)
Lung and pleura	9 (75.1%)
Lung and Liver	1 (8.3%)
Vertebra	1 (8.3%)
Soft tissue (infraclavicular tumour)	1 (8.3%)
Total	12 (100%)

Histologically confirmed cases include three metastases to the lung and one metastasis to the left infraclavicular region. Remaining cases were radiologically detected.  
PT, phyllodes tumours.

**Table 7** Grade of original and initial local recurrences of PT

Original tumour grade	Recurrent tumour grade	Number
Benign	Benign	27
Benign	Borderline	17
Benign	Malignant	4
Borderline	Borderline	10
Borderline	Malignant	2
Borderline	Benign	4
Malignant	Malignant	9
Total		73

PT, phyllodes tumours.

**Table 8** Univariate analysis of recurrence free survival of women with PT

Factor	No of patients	No of events	Median survival (months)	HR* (95% CI)	p Value
All	552	85	NR		
Age	552	85	NR	1.00 (0.98 to 1.02)	0.7006
Size	552	85	NR	1.00 (1.00 to 1.01)	0.1725
Grade					<b>&lt;0.0001</b>
Benign	399	46	NR	Reference	
Borderline	103	17	NR	1.67 (0.96 to 2.92)	
Malignant	50	19	NR	3.83 (2.24 to 6.53)	
Mitoses per 10 hpf	552	85	NR	1.05 (1.03 to 1.07)	<b>&lt;0.0001</b>
Surgical margin					<b>&lt;0.0001</b>
Negative	314	15	NR	Reference	
Positive	228	70	NR	7.14 (4.07 to 12.52)	
Type of surgery					0.0593
Excision	375	57	NR	Reference	
Mastectomy	62	15	NR	1.72 (0.98 to 3.04)	
Wide excision	114	10	NR	0.60 (0.31 to 1.17)	
Core biopsy	1	0	NR	—	
Grade					<b>&lt;0.0001</b>
Benign	426	48	NR	Reference	
Borderline	106	17	NR	1.60 (0.92 to 2.78)	
Malignant	54	20	NR	3.84 (2.28 to 6.47)	
Race					0.2095
Chinese	394	60	NR	Reference	
Malay	89	17	NR	1.29 (0.75 to 2.22)	
Indian	34	1	NR	0.19 (0.03 to 1.39)	
Others	35	4	NR	1.04 (0.38 to 2.87)	
Atypia					<b>&lt;0.0001</b>
Mild	424	48	NR	Reference	
Moderate	101	23	NR	2.16 (1.316 to 3.55)	
Marked	27	11	NR	4.42 (2.29 to 8.50)	
Hypercellularity					<b>0.0005</b>
Mild	302	31	NR	Reference	
Moderate	208	41	NR	2.22 (1.39 to 3.54)	
Marked	42	10	NR	2.83 (1.39 to 5.78)	
Overgrowth					<b>0.0003</b>
Absent	482	63	NR	Reference	
Present	70	19	NR	2.49 (1.49 to 4.15)	
Borders					<b>0.0047</b>
Circumscribed	314	33	NR	Reference	
Permeative	238	49	NR	1.87 (1.20 to 2.91)	
PASH					0.3569
Absent	329	47	NR	Reference	
Present	222	34	NR	0.81 (0.52 to 1.27)	

HR (hazard ratio) refers to recurrence risk relative to reference. It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR.

hpf, high-power fields; NR, not reached; PASH, pseudoangiomatous stromal hyperplasia.


**Table 9** Multivariate analysis of recurrence-free survival without interaction

Factor	No. of patients	No. of events	Median survival (months)	HR (95% CI)	p Value
Mitoses per 10 hpf	552	82	NR	1.03 (1.00 to 1.06)	<b>0.0580</b>
Surgical margin					
Negative	314	15		Reference	
Positive	238	67		8.37 (4.71 to 14.90)	<b>&lt;0.0001</b>
Atypia					
Mild	424	48	NR	Reference	
Moderate	101	23	NR	1.79 (1.01 to 3.16)	<b>0.0446</b>
Marked	27	11	NR	3.28 (1.48 to 7.23)	<b>0.0033</b>
Overgrowth					
Absent	482	63	NR	Reference	
Present	70	19	NR	2.28 (1.19 to 4.36)	<b>0.0126</b>
Hypercellularity					
Mild	302	31	NR	Reference	
Moderate	208	41	NR	1.21 (0.71 to 2.06)	0.4786
Marked	42	10	NR	0.47 (0.17 to 1.31)	0.1496

HR (hazard ratio) refers to recurrence risk relative to reference. It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR.

hpf, high-power fields; NR, not reached.


biologically reflected by another and incorporating surgical margin status, which represents complete or incomplete tumour removal. The nomogram model that has been built in this manner allows a risk assessment for an individual patient. It



**Figure 5** Nomogram for predicting recurrence-free survival (RFS) of patients with phyllodes tumours. To use the nomogram, locate the first variable. Draw a line straight upwards to the Points axis to determine the number of points received for the variable. Repeat this process for the other three variables and sum up the points achieved for each variable. The sum of these numbers is located on the Total Points axis, and a line is drawn downwards to the survival axes to determine the likelihood of 1-, 3-, 5- or 10-year RFS. 'For instance, a woman with a phyllodes tumour that demonstrates moderate stromal atypia (11 points), mitoses of 10 per 10 high-power fields (3 points), no stromal overgrowth (0 points) and positive surgical margin (40 points) will have a RFS (based on total points of 54 points) of just above 0.9 at 1 year, 0.7 at 3 years, 0.58 at 5 years and 0.5 at 10 years. Calculation of RFS can be automated through computerised programming.

## Original article

**Figure 6** Bootstrapped estimates of calibration accuracy at (A) 1 year (B) 3 years (C) 5 years and (D) 10 years. The ideal outcome (grey line), the observed outcome (black line) and the optimism corrected outcome (blue line) are depicted. This figure demonstrates how accurately predictions at different risk levels conform to observed outcomes for the nomogram. Mean and maximum deviations between observed and corrected outcomes are 0.03 and 0.02 (1 year), 0.04 and 0.05 (3 years), 0.04 and 0.07 (5 years), 0.04 and 0.08 (10 years).



helps clarify factors that are independently contributing to recurrence likelihood and provides a powerful tool for estimating outcomes.

The final elements used for the nomogram are the degree of stromal atypia (mild, moderate, marked), stromal mitoses per 10 high-power fields (assessed in the most mitotically active areas), stromal overgrowth (absent or present) and surgical margins (negative or positive), simply referred to as the AMOS criteria. Both stromal hypercellularity and tumour borders have been omitted from the model because of their lack of independent importance in predicting RFS and their exclusion using the AIC rule. Although mitotic rate did not achieve statistical significance, we included it as the p value was close to 0.05, and mitosis counting can be a fairly objective exercise. Counting mitoses is a familiar activity of the pathologist, who routinely accomplishes this in the grading of invasive breast cancer. It should therefore be an achievable goal for mitotic rates to be consistently and reproducibly assessed. Similarly, assessment of degree of atypia is another common component of histological evaluation of many tumours. Stromal overgrowth, while potentially variable due to different microscope types, is not a commonly observed feature, with only 65 (10%) cases

demonstrating this change in our series. The slight variation in absolute size of a low magnification field ( $\times 4$  objective and  $\times 10$  eyepiece) of a different microscope makes it unlikely to cause significant inconsistency, as when stromal overgrowth is present, it is often unequivocal.

Assessment of these individual parameters (AMOS criteria) that are added to derive a numerical point value in our nomogram to predict RFS for the individual patient eliminates the generalisation afforded by grade. The nomogram can be translated into risk counselling, allow informed discussions of management strategies and can also be used in future clinical trials. A key advantage of our study is the relatively homogeneous patient cohort, managed in a mostly uniform manner within a single institution. The availability of institutional medical records, together with high-quality follow-up data from the National Registry of Births and Deaths, allow robust recurrence-free follow-up and death information. Our exclusion on non-local residents without follow-up data in the statistical model reduces the possibility of inaccurate follow-up.

We do not advocate that PT grading be replaced by our proposed predictive nomogram. Grade has established utility in assigning a biological category to the tumour, as evidenced by its

**Table 10** Nomogram and total histological score as predictors of recurrence-free survival

	No of events/ no. of patients	HR* (95% CI)	p Value	5-year survival	Concordance index†
Nomogram	85/552	1.05 (1.04 to 1.06)	<0.001	0.99	0.79
Total histological score	85/552	1.27 (1.15 to 1.40)	<0.001	0.99	0.65

\*HR is the increase in recurrence risk with each unit increase in specific score variables. It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR.

†The concordance index provides a metric for the concordance between predicted and observed outcomes for each survival model.



**Table 11** Comparison of nomogram and total histological score as predictors of recurrence-free survival

Likelihood			p Value		Adequacy index	
Full model*	Nomogram	Total score	Nomogram†	Total score‡	Nomogram§	Total score¶
94.15	94.01	21.38	<0.0001	0.7026	99.9%	22.7%

\*The full model comprises both total score and nomogram as predictors of the outcome of recurrence.

†The comparison of a nested model with the predictor of total histological score only with the full model with predictors of both total histological score and nomogram. A significant value implies that the full model has more explanatory power.

‡The comparison of a nested model with the predictor of nomogram only with the full model with predictors of both total histological score and nomogram. A non-significant value implies that the full model has similar explanatory power as the nested model.

§The proportion of the variation explained by the nomogram compared to that explained by both total histological score and nomogram.

¶The proportion of the variation explained by the total histological score compared to that explained by both total score and nomogram.

significant correlation with RFS in our study. It is also important to continue to categorise PT into discrete pathological groups for comparison across studies and to allow investigation of biological markers. Progression of PT into higher histological grades with recurrent episodes, as seen in 23 of 73 (31.5%) of initial recurrences in our series, is also another area that requires additional scrutiny and will benefit from continued pathological segregation of PT.

Our nomogram has a superior performance compared with an arbitrary but simple total histological score obtained from adding up scores of the five histological parameters. This confirms that the biological impact of each microscopic parameter is more complex, with varying influence on RFS, and is therefore not so easily equated with a linear additive scale.

The importance of surgical margin status on outcome is reaffirmed in our current study.<sup>1</sup> Apart from its statistically significant relationship with RFS in both univariate and multivariate analysis, inclusion of surgical margin status into the nomogram improved the predictive value. As this is a retrospective study, more details on surgical margin status such as clearance distance could not be assessed, and it was therefore not within the scope of this investigation to comment on an ideal or

### Take-home messages

- Breast phyllodes tumours (PT) can be classified into benign, borderline and malignant grades based on a constellation of histological findings.
- Stromal atypia, mitoses, overgrowth and surgical margins (AMOS) are important predictive factors for PT recurrence.
- A nomogram based on the AMOS criteria can predict the likely recurrence-free survival of individual patients diagnosed with PT.

minimum margin clearance for PT. It has been suggested that a 1-cm margin is the recommended clearance for surgical excision of PT.<sup>45</sup>

Limitations of our study relate to the relatively few events that have occurred within the series, due largely to the innate biology of the tumour that has a reported overall recurrence rate from 10% to 21%.<sup>1 2</sup> Amalgamation of local with distant recurrences as well as deaths may lead to a question of what is the true end point being interrogated. The overwhelming number of local recurrences among all recurrent episodes in our study, however, attests to the nomogram's ability in predicting local recurrences. While death from disease is the ultimate event we wish to eliminate, our previous and current experience with PT is that local recurrence precedes distant metastases that cause demise, with the exception of initially malignant tumours that can metastasise without an intervening locally recurrent episode.<sup>1</sup> Another limitation of the nomogram is that it has yet to be validated by an external cohort.

In conclusion, we describe the clinicopathological features and follow-up details of a large series of breast PT. Using the data, we undertook statistical modelling and developed a nomogram that integrates pathological features of AMOS into a predictive risk model that can be used for patient counselling and clinical management. Continued work on PT will help refine the nomogram which we believe can become a useful adjunct in the management of this group of women.

**Competing interests** None.


**Ethics approval** Ethics approval was provided by Centralised Institutional Review Board, SingHealth.

**Contributors** All authors contributed to the manuscript.

**Provenance and peer review** Not commissioned; externally peer reviewed.

### REFERENCES

1. Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumors of the breast: the role of pathologic parameters. *Am J Clin Pathol* 2005;**123**:529–40.
2. Tavassoli FA, Devilee P; World Health Organization, International Agency for Research on Cancer, International Academy of Pathology. *Pathology and Genetics of Tumours of the Breast and Female Genital Organs*. Lyon: IARC Press, 2003.



**Figure 7** Pictorial representation of the comparison of the performance of the full model comprising nomogram and total histological score, relative to individual nested models with either nomogram or total histological score. An individual nested model comprising nomogram essentially performs equally well as the full model in predicting recurrence ( $p=0.7026$ ); there is little additional variation explained by adding total histological score to the individual nested model with a nomogram only. Conversely, a model comprising total histological score only has only 22.7% of the explanatory power of the full model.

## Original article

3. **Lee AH**, Hodi Z, Ellis IO, *et al*. Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. *Histopathology* 2007;**51**:336–44.
4. **Jara-Lazaro AR**, Akhilesh M, Thike AA, *et al*. Predictors of phyllodes tumours on core biopsy specimens of fibroepithelial neoplasms. *Histopathology* 2010;**57**:220–32.
5. **Jacobs TW**, Chen YY, Guinee DG Jr, *et al*. Fibroepithelial lesions with cellular stroma on breast core needle biopsy: are there predictors of outcome on surgical excision? *Am J Clin Pathol* 2005;**124**:342–54.
6. **Huang KT**, Dobrovic A, Yan M, *et al*. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. *Breast Cancer Res Treat* 2010;**124**:555–65.
7. **Chua CL**, Thomas A, Ng BK. Cystosarcoma phyllodes—Asian variations. *Aust N Z J Surg* 1988;**58**:301–5.
8. **Chong LY**, Cheok PY, Tan WJ, *et al*. Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. *Breast Cancer Res Treat*. Published Online First: 15 May 2011.
9. **Ang MK**, Ooi AS, Thike AA, *et al*. Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. *Breast Cancer Res Treat* 2011;**129**:319–29.
10. **Sawyer EJ**, Poulosom R, Hunt FT, *et al*. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. *J Pathol* 2003;**200**:59–64.
11. **Sawyer EJ**, Hanby AM, Rowan AJ, *et al*. The Wnt pathway, epithelial–stromal interactions, and malignant progression in phyllodes tumours. *J Pathol* 2002;**196**:437–44.
12. **Sawyer EJ**, Hanby AM, Poulosom R, *et al*. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. *J Pathol* 2003;**200**:627–32.
13. **Sawyer EJ**, Hanby AM, Ellis P, *et al*. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. *Am J Pathol* 2000;**156**:1093–8.
14. **Jones AM**, Mitter R, Springall R, *et al*; Phyllodes Tumour Consortium. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. *J Pathol* 2008;**214**:533–44.
15. **Jones AM**, Mitter R, Poulosom R, *et al*. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours. *J Pathol* 2008;**216**:408–17.
16. **Jara-Lazaro AR**, Tan PH. Molecular pathogenesis of progression and recurrence in breast phyllodes tumors. *Am J Transl Res* 2009;**1**:23–34.
17. **Karim RZ**, Scolyer RA, Tse GM, *et al*. Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours. *Pathology* 2009;**41**:105–17.
18. **Karim RZ**, Gerega SK, Yang YH, *et al*. Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. *J Clin Pathol* 2009;**62**:1016–20.
19. **Tse GM**, Lui PC, Vong JS, *et al*. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors. *Breast Cancer Res Treat* 2009;**114**:441–8.
20. **Tse GM**, Chaiwun B, Lau KM, *et al*. Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. *J Clin Pathol* 2007;**60**:1051–6.
21. **Tan PH**, Jayabaskar T, Yip G, *et al*. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. *Mod Pathol* 2005;**18**:1527–34.
22. **Kersting C**, Kuijper A, Schmidt H, *et al*. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. *Lab Invest* 2006;**86**:54–61.
23. **Karim RZ**, Gerega SK, Yang YH, *et al*. p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. *Histopathology* 2010;**56**:868–75.
24. **Tse GM**, Wong FC, Tsang AK, *et al*. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. *J Clin Pathol* 2005;**58**:600–4.
25. **Tse GM**, Tsang AK, Putti TC, *et al*. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. *J Clin Pathol* 2005;**58**:185–9.
26. **Tse GM**, Putti TC, Lui PC, *et al*. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. *Mod Pathol* 2004;**17**:827–31.
27. **Tse GM**, Putti TC, Kung FY, *et al*. Increased p53 protein expression in malignant mammary phyllodes tumors. *Mod Pathol* 2002;**15**:734–40.
28. **Tse GM**, Lui PC, Scolyer RA, *et al*. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. *Mod Pathol* 2003;**16**:1007–13.
29. **Tse GM**, Lui PC, Lee CS, *et al*. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. *Hum Pathol* 2004;**35**:1053–7.
30. **Tse GM**, Lee CS, Kung FY, *et al*. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. *Am J Clin Pathol* 2002;**118**:522–6.
31. **Reinfuss M**, Mitus J, Smolak K, *et al*. Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases. *Eur J Cancer* 1993;**29A**:1252–6.
32. **Reinfuss M**, Mitus J, Duda K, *et al*. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. *Cancer* 1996;**77**:910–16.
33. **Keelan PA**, Myers JL, Wold LE, *et al*. Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. *Hum Pathol* 1992;**23**:1048–54.
34. **Hawkins RE**, Schofield JB, Fisher C, *et al*. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. *Cancer* 1992;**69**:141–7.
35. **Chaney AW**, Pollack A, McNeese MD, *et al*. Primary treatment of cystosarcoma phyllodes of the breast. *Cancer* 2000;**89**:1502–11.
36. **Pietruszka M**, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. *Cancer* 1978;**41**:1974–83.
37. **Tan MH**, Li H, Choong CV, *et al*. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. *Cancer* 2011;**23**:5314–24.
38. **Tan EY**, Tan PH, Yong WS, *et al*. Recurrent phyllodes tumours of the breast: pathological features and clinical implications. *ANZ J Surg* 2006;**76**:476–80.
39. **Barth RJ Jr**. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. *Breast Cancer Res Treat* 1999;**57**:291–5.
40. **Kleer CG**, Giordano TJ, Braun T, *et al*. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast. *Mod Pathol* 2001;**14**:185–90.
41. **Moffat CJ**, Pinder SE, Dixon AR, *et al*. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. *Histopathology* 1995;**27**:205–18.
42. **Zurrida S**, Bartoli C, Galimberti V, *et al*. Which therapy for unexpected phyllode tumour of the breast? *Eur J Cancer* 1992;**28**:654–7.
43. **Mangi AA**, Smith BL, Gadd MA, *et al*. Surgical management of phyllodes tumors. *Arch Surg* 1999;**134**:487–92; discussion 492–3.



## Correction

---

PH Tan, AA Thike, WJ Tan *et al.* Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. *J Clin Pathol* 2012;65:69–76. There are errors in Tables 1, 8 and 9 of this paper, the following information has been corrected. In Table 1 under 'Clinicopathological features', Size (mm) (mean 52, median 40, range 3–250) has been changed to: Size (mm) (mean 52, median 40, range 8–250). In Table 8 under 'Factor', the second entry of Grade has been deleted. The following text has been removed from the footnote: 'It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR.' The table footnote now reads: HR (hazard ratio) refers to recurrence risk relative to reference. hpf, high-power fields; NR, not reached; PASH, pseudoangiomatous stromal hyperplasia. In Table 9, the following text has been removed from the footnote: It should be noted that the nomogram has a score range between 0 and 100, but the total histological score has a more limited range between 5 and 13, accounting for the apparently higher HR. The footnote now reads: HR (hazard ratio) refers to recurrence risk relative to reference. hpf, high-power fields; NR, not reached.

*J Clin Pathol* 2013;66:455–456. doi:10.1136/jclinpath-2011-200368corr1

**Table 1** Clinicopathological features of 605 cases of phyllodes tumour stratified according to histological grade

Clinicopathological features	Benign	Borderline	Malignant	p Value
Age (years) (mean 42, median 43, range 15–79)				<0.001
<mean age	227 (37.5%)	36 (5.9%)	16 (2.6%)	
≥mean age	213 (35.2%)	75 (12.5%)	38 (6.3%)	
Ethnicity				0.724
Chinese	307 (50.7%)	81 (13.4%)	37 (6.1%)	
Malay	66 (11.2%)	19 (3.1%)	10 (1.6%)	
Indian	31 (5.1%)	3 (0.5%)	0 (0%)	
Others	36 (5.9%)	8 (1.3%)	7 (1.1%)	
Size (mm) (mean 52, median 40, range 8–250)				<0.001
<mean size	343 (56.7%)	54 (8.9%)	16 (2.6%)	
≥mean size	97 (16.1%)	57 (9.4%)	38 (6.3%)	
Microscopic borders				<0.001
Circumscribed	283 (46.8%)	49 (8.1%)	20 (3.3%)	
Permeative	157 (26.0%)	62 (10.2%)	34 (5.6%)	
Stromal hypercellularity				<0.001
Mild	302 (49.9%)	21 (3.5%)	3 (0.5%)	
Moderate	131 (21.7%)	75 (12.4%)	25 (4.1%)	
Marked	7 (1.1%)	15 (2.5%)	26 (4.3%)	
Stromal atypia				<0.001
Mild	412 (68.1%)	54 (8.9%)	0 (0%)	
Moderate	28 (4.8%)	54 (8.9%)	30 (4.9%)	
Marked	0 (0%)	3 (0.5%)	24 (3.9%)	
Stromal overgrowth				<0.001
Absent	440 (72.8%)	86 (14.2%)	14 (2.3%)	
Present	0 (0%)	25 (4.1%)	40 (6.6%)	
Mitotic activity/10 hpf				<0.001
0–4	402 (66.4%)	31 (5.1%)	5 (0.8%)	
5–9	34 (5.6%)	51 (8.4%)	15 (2.5%)	
≥10	4 (0.7%)	29 (4.9%)	34 (5.6%)	
Surgical margins				0.511
Complete (Not involved)	257 (42.5%)	58 (9.6%)	34 (5.6%)	
Focal involvement	168 (27.7%)	44 (7.3%)	16 (2.6%)	
Diffuse involvement	15 (2.5%)	9 (1.5%)	4 (0.7%)	

hpf, high-power fields.

**Table 9** Multivariate analysis of recurrence-free survival without interaction

Factor	No. of patients	No. of events	Median survival (months)	HR (95% CI)	p Value
Mitoses per 10 hpf	552	82	NR	1.03 (1.00 to 1.06)	<b>0.0580</b>
Surgical margin					
Negative	314	15		Reference	
Positive	238	67		8.37 (4.71 to 14.90)	<b>&lt;0.0001</b>
Atypia					
Mild	424	48	NR	Reference	
Moderate	101	23	NR	1.79 (1.01 to 3.16)	<b>0.0446</b>
Marked	27	11	NR	3.28 (1.48 to 7.23)	<b>0.0033</b>
Overgrowth					
Absent	482	63	NR	Reference	
Present	70	19	NR	2.28 (1.19 to 4.36)	<b>0.0126</b>
Hypercellularity					
Mild	302	31	NR	Reference	
Moderate	208	41	NR	1.21 (0.71 to 2.06)	0.4786
Marked	42	10	NR	0.47 (0.17 to 1.31)	0.1496

HR (hazard ratio) refers to recurrence risk relative to reference.

hpf, high-power fields; NR, not reached.

**Table 8** Univariate analysis of recurrence free survival of women with PT

Factor	No of patients	No of events	Median survival (months)	HR* (95% CI)	p Value
All	552	85	NR		
Age	552	85	NR	1.00 (0.98 to 1.02)	0.7006
Size	552	85	NR	1.00 (1.00 to 1.01)	0.1725
Grade					<b>&lt;0.0001</b>
Benign	399	46	NR	Reference	
Borderline	103	17	NR	1.67 (0.96 to 2.92)	
Malignant	50	19	NR	3.83 (2.24 to 6.53)	
Mitoses per 10 hpf	552	85	NR	1.05 (1.03 to 1.07)	<b>&lt;0.0001</b>
Surgical margin					<b>&lt;0.0001</b>
Negative	314	15	NR	Reference	
Positive	228	70	NR	7.14 (4.07 to 12.52)	
Type of surgery					0.0593
Excision	375	57	NR	Reference	
Mastectomy	62	15	NR	1.72 (0.98 to 3.04)	
Wide excision	114	10	NR	0.60 (0.31 to 1.17)	
Core biopsy	1	0	NR	—	
Race					0.2095
Chinese	394	60	NR	Reference	
Malay	89	17	NR	1.29 (0.75 to 2.22)	
Indian	34	1	NR	0.19 (0.03 to 1.39)	
Others	35	4	NR	1.04 (0.38 to 2.87)	
Atypia					<b>&lt;0.0001</b>
Mild	424	48	NR	Reference	
Moderate	101	23	NR	2.16 (1.316 to 3.55)	
Marked	27	11	NR	4.42 (2.29 to 8.50)	
Hypercellularity					<b>0.0005</b>
Mild	302	31	NR	Reference	
Moderate	208	41	NR	2.22 (1.39 to 3.54)	
Marked	42	10	NR	2.83 (1.39 to 5.78)	
Overgrowth					<b>0.0003</b>
Absent	482	63	NR	Reference	
Present	70	19	NR	2.49 (1.49 to 4.15)	
Borders					<b>0.0047</b>
Circumscribed	314	33	NR	Reference	
Permeative	238	49	NR	1.87 (1.20 to 2.91)	
PASH					0.3569
Absent	329	47	NR	Reference	
Present	222	34	NR	0.81 (0.52 to 1.27)	

HR (hazard ratio) refers to recurrence risk relative to reference.

hpf, high-power fields; NR, not reached; PASH, pseudoangiomatous stromal hyperplasia.



## Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins

Puay Hoon Tan, Aye Aye Thike, Wai Jin Tan, et al.

*J Clin Pathol* 2012 65: 69-76 originally published online November 2, 2011

doi: 10.1136/jclinpath-2011-200368

---

Updated information and services can be found at:  
<http://jcp.bmj.com/content/65/1/69.full.html>

---

### References

*These include:*

This article cites 41 articles, 7 of which can be accessed free at:  
<http://jcp.bmj.com/content/65/1/69.full.html#ref-list-1>

Article cited in:  
<http://jcp.bmj.com/content/65/1/69.full.html#related-urls>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>